CD24 and cancer: These studies showed decreased proliferation, motility, and tumorigenicity of cancer cell lines in mouse models, and one study showed specifically that combination therapy of CD24 mAb and gemcitabine strongly potentiated its anti-cancer efficacy in a mouse lung cancer model [138].